Home
Products
Learn
About
Pricing
Log In
ARX
Asset Logo

Aroa Biosurgery Limited

πŸ‡¦πŸ‡Ί ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-8.55%
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

14
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.

πŸ“ˆ Performance

Price History

-41.33%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.44

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in ARX

14

πŸ“Š Total Capital Earnings

$20K

πŸ”ƒ Average investment frequency

17 weeks

πŸ’΅ Average investment amount

$4,432

⏰ Last time a customer invested in ARX

59 days
ARX investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

11%

100k - 150k

11%

50k - 100k

44%

Less than 50k

28%
πŸ‘Ά Age of investors

18 - 25

26 - 34

36%

35 - 90

64%
πŸ™‹ Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in ARX also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

9.04%

πŸ“Š Share price

$103.68 AUD

🧱 MATERIALS

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

πŸ“ˆ HIGH PRICE GROWTH

⛳️ DIVERSIFIED

Find Out More

Paladin Energy Ltd. engages in the development and operation of uranium mines. The company is headquartered in Perth, Western Australia. The firm also owns a portfolio of uranium exploration and development assets in Canada and Australia. Its segments include Exploration, Namibia and Australia. The LHM is located in central western Namibia approximately 80 kilometers (km) east of Swakopmund and 85 km northeast of the Walvis Bay major deepwater harbor. Its Patterson Lake South (PLS) Project hosts the Triple R deposit, a large, high-grade and near-surface uranium deposit. The property comprises over 17 contiguous claims totaling 31,039 hectares. Its exploration projects include West Cluff, Larocque, Seahawk, Merlin, Corsair, Typhoon, Michelin, Manyingee and Mount Isa. The Company, through its subsidiary Aurora Energy Ltd, holds a 100% interest in over 98,320 hectares of mineral exploration licenses. These are located within the Central Mineral Belt of Labrador, Canada.

πŸ™Œ Performance (5Yr p.a)

901.48%

πŸ“Š Share price

$5.41 AUD

⚑️ ENERGY

Santos Ltd. engages in the exploration, development, transportation, and marketing of natural gas. The company is headquartered in Adelaide, South Australia and currently employs 3,958 full-time employees. Supporting these three business units are two functional divisions: Santos Energy Solutions and Upstream Gas and Liquids. The Cooper Basin produces natural gas, gas liquids and crude oil. Gas is sold primarily to domestic retailers, industry and for the production of liquefied natural gas, while gas liquids and crude oil are sold in domestic and export markets. Its GLNG project in Queensland produces liquefied natural gas (LNG) for export to global markets from the LNG plant at Gladstone and is also sold to the domestic market. Northern Australia and Timor-Leste is centered on the Bayu-Undan/Darwin LNG (DLNG) project.

πŸ™Œ Performance (5Yr p.a)

4.34%

πŸ“Š Share price

$6.39 AUD

⚑️ ENERGY

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

πŸ™Œ Performance (5Yr p.a)

130.18%

πŸ“Š Share price

$12.84 AUD

πŸ“¦ LOGISTICS

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. The company is headquartered in Perth, Western Australia. The Company’s operations include Mt Weld, Lynas Malaysia, Kalgoorlie and Lynas USA. The company focuses on developing the Mt Weld resource, which includes ongoing exploration, production of mixed rare earths concentrates, and an expansion project to increase concentrate feedstock production to support 12,000 tons per annum of finished NdPr oxide. The Lynas Malaysia advanced materials plant is located on a 100-hectare site in the Gebeng Industrial Estate, a purpose-built petrochemical industry zone near Kuantan, on the east coast of Malaysia. Its rare earths processing facility in Kalgoorlie undertakes value-added processing of rare earths. The firm's subsidiaries include Lynas Malaysia Sdn Bhd, Lynas Africa Ltd, Lynas Kalgoorlie Pty Ltd and Lynas USA LLC.

πŸ™Œ Performance (5Yr p.a)

58.50%

πŸ“Š Share price

$8.13 AUD

πŸ•ŠοΈ SOCIALLY AWARE

⛏️ MINING

Want more shares? Try these...

ARXN

Compare
Add to watchlist